Cargando…
Elucidation of a Human Urine Metabolite as a Seryl-Leucine Glycopeptide and as a Biomarker of Effective Anti-Tuberculosis Therapy
[Image: see text] The evaluation of new tuberculosis (TB) therapies is limited by the paucity of biomarkers to monitor treatment response. Previous work detected an uncharacterized urine metabolite with a molecular mass of 874.3547 Da that showed promise as a biomarker for successful TB treatment. U...
Autores principales: | Fitzgerald, Bryna L., Islam, M. Nurul, Graham, Barbara, Mahapatra, Sebabrata, Webb, Kristofor, Boom, W. Henry, Malherbe, Stephanus T., Joloba, Moses L., Johnson, John L., Winter, Jill, Walzl, Gerhard, Belisle, John T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2018
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412501/ https://www.ncbi.nlm.nih.gov/pubmed/30585483 http://dx.doi.org/10.1021/acsinfecdis.8b00241 |
Ejemplares similares
-
Correction to “Elucidation of a Novel Human
Urine Metabolite as a Seryl-Leucine Glycopeptide and as a Biomarker
of Effective Anti-Tuberculosis Therapy”
por: Fitzgerald, Bryna L., et al.
Publicado: (2019) -
Elucidating the Structure of N(1)-Acetylisoputreanine:
A Novel Polyamine Catabolite
in Human Urine
por: Fitzgerald, Bryna L., et al.
Publicado: (2017) -
A metabolic biosignature of early response to anti-tuberculosis treatment
por: Mahapatra, Sebabrata, et al.
Publicado: (2014) -
Identification of Urine Metabolites as Biomarkers of Early Lyme Disease
por: Pegalajar-Jurado, Adoracion, et al.
Publicado: (2018) -
A pilot metabolomics study of tuberculosis immune reconstitution inflammatory syndrome
por: Silva, Carlos A.M., et al.
Publicado: (2019)